AbbVie stock remains attractive despite recent guidance cuts.

AbbVie stock remains attractive despite recent guidance cuts. The pharmaceutical giant delivered robust Q4 results with 10% revenue growth and a 38.3% adjusted operating margin, demonstrating underlying operational strength. EPS guidance reductions stem from normal research and development expenses and milestone payments, not fundamental business deterioration. The company's pipeline shows considerable promise, with positive trial results for Skyrizi and ABBV-295 offsetting competitive pressures. Trading at a forward P/E of 13.85, AbbVie sits at multiyear valuation lows, presenting compelling risk-reward dynamics for investors seeking exposure to durable pharmaceutical growth with sustainable dividend characteristics.